title: Comparison of two mycophenolate mofetil dosing regimens after hematopoietic cell transplantation.
abstract: Mycophenolic acid (MPA) is the active component of mycophenolate mofetil (MMF). Low MPA exposure is associated with a higher incidence of acute GVHD and possibly worse engraftment. Therapeutic plasma targets have been proposed in hematopoietic cell transplantation (HCT), however, are difficult to achieve in adult patients with MMF doses of 2 g/day. Mycophenolate pharmacokinetics was prospectively studied in adults undergoing nonmyeloablative HCT who received MMF 3 g/day with CYA. The first 15 individuals received 1.5 g every 12 h and the second 15 received 1 g every 8 h. Sampling was performed in each patient with i.v. and oral administration. There were no differences in total or unbound MPA 24-h cumulative area under the curves (AUCs), concentrations at steady state (Css) or troughs between the two dosing regimens (all P>0.01). The previously proposed total MPA Css target of 3 microg/ml and trough >or=1 micro/ml were achieved in only 13-27% and 20-53% of patients, respectively, on 3 g/day. However, the 3 g/day regimens readily achieved satisfactory unbound 24-h cumulative AUC targets of 0.600 microg(*)h/ml in 87-100% of subjects. There appears to be no significant difference in daily MPA exposure when MMF of 3 g/day is divided into two or three equal doses.
authors.affiliation: Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA. jacob117@umn.edu
authors.forename: P
authors.initials: P
authors.lastname: Jacobson
authors.forename: S F
authors.initials: SF
authors.lastname: El-Massah
authors.forename: J
authors.initials: J
authors.lastname: Rogosheske
authors.forename: A
authors.initials: A
authors.lastname: Kerr
authors.forename: J
authors.initials: J
authors.lastname: Long-Boyle
authors.forename: T
authors.initials: T
authors.lastname: DeFor
authors.forename: C
authors.initials: C
authors.lastname: Jennissen
authors.forename: C
authors.initials: C
authors.lastname: Brunstein
authors.forename: J
authors.initials: J
authors.lastname: Wagner
authors.forename: M
authors.initials: M
authors.lastname: Tomblyn
authors.forename: D
authors.initials: D
authors.lastname: Weisdorf
mesh_terms: D000328:Adult; D000368:Aged; D015331:Cohort Studies; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D005260:Female; D006086:Graft vs Host Disease / Q000517:prevention & control; D019337:Hematologic Neoplasms / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D011446:Prospective Studies; D013997:Time Factors; D014184:Transplantation, Homologous
chemical_list: D009173:Mycophenolic Acid